Advances in Interventional Cardiology · 2016 · 16 citations · 27 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical CardiologyInterventional CardiologyAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyAntithrombotic TherapyAtrial FibrillationThrombosis ManagementAnticoagulation During Coronary InterventionAtrial Fibrillation AssessmentMonitoring Of Anticoagulant TherapyPost-percutaneous Coronary Intervention Antithrombotic TherapyTherapeutic AnticoagulationTriple Antithrombotic Therapy
INTRODUCTION: Triple anticoagulation therapy (TT), comprising dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC), is essential in atrial fibrillation (AF) patients after percutaneous coronary intervention (PCI), but it increases the bleeding risk. AIM: To assess TT models, in- and out-hospital bleeding and thromboembolic complications, and TT alterations. MATERIAL AND METHODS: During 12 months, consecutive AF post-PCI patients were scheduled for TT. Alterations in TT and thromboembolic events (death, myocardial infarction, ischemic stroke, in-stent thrombosis, peripheral embolization) were recorded. Major, non-major and minor bleeding episodes were assessed. RESULTS: = 0.89). CONCLUSIONS: Our study indicates that TT is associated with high mortality and bleeding rates in a relatively short period of time. Discontinuation of any TT drug did not increase the thromboembolic event rate, while it was associated with reduced risk of major bleeding.
27
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.2K citations · Full text
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text